Joint application:
- with methotrexate at a dose of 15 mg per week or more: the hemolytic cytotoxicity of methotrexate is increased (the renal clearance of methotrexate and methotrexate is replaced by salicylates in association with blood plasma proteins);
- with anticoagulants, for example, heparin: increased risk of bleeding due to inhibition of platelet function, damage to the mucosa of the gastrointestinal tract, displacement of anticoagulants (oral) from the connection with blood plasma proteins;
- with other non-steroidal anti-inflammatory drugs: as a result of synergistic interaction, the risk of ulceration and bleeding of the stomach increases;
- with uricosuric medicines, for example benzbromarone: reduces the uricosuric effect;
- with digoxin: the concentration of digoxin is increased due to decreased renal excretion;
- with hypoglycemic drugs, for example insulin: increased hypoglycemic effect of hypoglycemic drugs due to hypoglycemic effect of acetylsalicylic acid;
- with preparations of thrombolytics group: the risk of bleeding increases;
- with systemic glucocorticosteroids, excluding hydrocortisone, used as a substitute therapy for Addison's disease when using glucocorticosteroids, the level of salicylates in the blood decreases due to an increase in the excretion of the latter;
- with inhibitors of the angiotensin-converting enzyme: the glomerular filtration decreases due to the inhibition of prostaglandins and, as a consequence, the antihypertensive effect decreases;
- with valproic acid: the toxicity of valproic acid increases;
- with ethanol (alcoholic beverages): the risk of damaging effect on the mucosa of the gastrointestinal tract increases and the risk of gastrointestinal bleeding increases,
- enhances the effects of narcotic analgesics, thrombolytic agents and platelet aggregation inhibitors, sulfonamides (including co-trimoxazole);
- increases the concentration of barbiturates, lithium salts in plasma;
- antacids containing magnesium and / or aluminum slow down and worsen the absorption of acetylsalicylic acid;
- Myelotoxic drugs increase the manifestation of hematotoxicity of the drug.